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PURPOSE: There is an increasing need for accurate
prognostic stratification of patients with Stage II colorectal
cancer to identify a subgroup of high-risk patients who may
benefit from adjuvant therapies. This study was designed to
evaluate the prognostic impact of a wide spectrum of
pathologic parameters in a consecutive series of homoge-
nously treated and well-characterized patients with Stage
IIA (T3N0M0) colorectal cancer. METHODS: The study
included 238 patients operated on by a single surgeon for
Stage IIA colorectal tumors. The median postoperative
follow-up was 110 (range, 96–120) months. At least 12
lymph nodes were harvested and examined in all the
resection specimens. The prognostic value of 13 pathologic
parameters, including lymph node occult disease (micro-
metastases) detected by immunohistochemistry, was inves-
tigated. RESULTS: Multivariate analysis identified tumor
growth pattern (expanding or infiltrating; P = 0.01) and
extent of tumor spread beyond muscularis propria (e5 mm
or >5 mm; P = 0.04) as the only factors having independent
prognostic value. The combination of these two easily
determined parameters allowed us to identify two groups
of patients at low risk or high risk of tumor recurrence. The
eight-year survival rates were 83.3 and 53.4 percent for the
two groups, respectively. The high-risk group comprised
those patients with infiltrating tumors and extramural
tumor spread > 5 mm. CONCLUSIONS: We propose a
new and simple prognostic model to identify patients with
high-risk Stage IIA colorectal cancer for whom adjuvant
therapies may be justified and effective. [Key words:
Colorectal cancer; Prognosis; Lymph node micrometasta-
ses; Pathologic parameters]
T he Dukes staging system was proposed morethan 70 years ago and, since then, has been the
most widely employed prognostic classification after
surgery for colorectal cancer.1 This staging system is
composed of two fundamental parameters, tumor
penetration of the bowel wall and lymph node (LN)
involvement. Although several alternative pathologic
and molecular prognostic factors have been pro-
posed in recent years, these two parameters remain
the most powerful prognostic indicators.2 In partic-
ular, LN status is considered the most important
determinant of the decision to institute postoperative
therapies in both colon and rectal cancer. However,
one major flaw of the Dukes classification is that a
great proportion of colorectal carcinomas, approxi-
mately 40 to 50 percent in most series, are classified
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as Dukes B, i.e., tumors extending beyond the wall
with negative LNs.3–6 Unfortunately, this is a broad
category with respect to patient clinical outcome
with a reported five-year survival rate ranging
between 60 and 75 percent.3–7 This is primarily
caused by the fact that Dukes B Stage encompasses
a wide spectrum of disease, from early penetration
through the bowel wall to extensive tumors with
involvement of the serosa, surgical margins, or
adjacent organs. Therefore, there is a need to better
predict the prognosis of these patients.
The recently revised American Joint Committee on
Cancer (AJCC) sixth edition cancer staging system8
has stratified Stage II, i.e., Dukes B Stage, into two
subsets—Stage IIA and Stage IIB—on the basis of
whether the tumor is T3 or T4, respectively. Tumors
classified as Stage IIA, i.e., invading through the
muscularis propria into the subserosa or nonperitoneal-
ized pericolic/perirectal tissues, have a significantly
better prognosis than Stage IIB tumors, which directly
invade the peritoneum or other organs/structures.9 A
possible explanation for this finding is that Stage IIB
tumors may not have received proper en bloc surgical
resection, so that residual disease was not excised.9
Recently, several clinical studies have addressed
the issue of whether tumor relapse in Stage II tumors
is related, at least in part, to the presence of LN occult
metastases, i.e., single tumor cells or cell clusters,
which are not revealed by routine hematoxylin-eosin
staining of histology sections.10–16 Unfortunately,
previously reported results on the prognostic and
clinical impact of LN occult tumor cells, identified
by immunohistochemistry or reverse transcriptase-
polymerase chain reaction, are controversial.10–16
This discrepancy may be the result of the fact that
the majority of published studies have not subdi-
vided nodal occult tumor cells into micrometastases
(MCM) or isolated tumor cells on the basis of their
dimensions as recently recommended by the new
TNM-AJCC classification.8 Isolated tumor cells are
classified as single tumor cells or cell clusters
measuring < 0.2 mm and are given a pN0 designation
because their prognostic significance is still undeter-
mined.17 MCM are defined as clusters of cells that
measure > 0.2 mm but < 2.0 mm and are designated by
pN1 (mi) because they have shown potential malig-
nant capability.17
This study was designed to evaluate the prognostic
impact of a wide spectrum of pathologic parameters,
including LN MCM, in a large series of patients
curatively operated on for Stage IIA colorectal
cancer. In particular, our goal was to identify a
subset of patients at high risk of tumor recurrence for
whom adjuvant chemotherapy may be of benefit.
PATIENTS AND METHODS
Between 1988 and 1997, a total of 587 consecutive
patients underwent potentially curative resection of
colorectal tumors by the same surgeon (CC) at the
Department of General Surgery, University of Flor-
ence, Italy; 238 patients had tumors classified as
Stage IIA (T3N0M0), according to the sixth edition of
the AJCC staging system,8 and were included in the
study (131 males; 55 percent; median age, 67 (range,
38–88) years). Cases with synchronous or metachro-
nous tumors, familial adenomatous polyposis, or
hereditary nonpolyposis colorectal cancer were ex-
cluded. Tumor distribution was as follows: 68 (28.6
percent) in the proximal colon (up to the splenic
flexure), 90 (37.8 percent) in the distal colon (up to
the end of sigmoid colon), and 80 (33.6 percent) in
the rectum. Surgical resection was defined as radical
when there was no evidence of distant metastases
and the clearance of the tumor was complete, both
macroscopically and histologically. Complete circum-
ferential excision of the mesorectum was performed
in all patients with tumors of the middle and lower
rectum. Both the longitudinal and radial margins of
all resected specimens were microscopically free of
tumor. A distal clearance of at least 2 cm of healthy
mucosa from the lower edge of the tumor was
provided in all patients. Each patient was followed
up for at least eight years (median value, 110 (range,
96–120) months) or until death. Only deaths attrib-
utable to recurrent cancer were counted as events in
the process of survival evaluation. All surviving
patients had been thoroughly informed about the
study and gave written consent for the investigation
in accordance with the ethical guidelines of our
university. No patient received preoperative or
postoperative radiotherapy or chemotherapy.
Pathologic Evaluation
The resection specimens were fixed in 10 percent
buffered formalin for 24 hours and an adequate
number of sections was sampled from each tumor
(mean, 6 (range, 4–12) sections) for microscopic
examination. All tissue sections were embedded in
paraffin and stained with hematoxylin-eosin. The
mesocolic/mesorectal fat was dissected meticulously
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by using a manual technique, and a median of 18 LNs
(range, 12–42) was harvested and examined per
tumor specimen. Cases with fewer than 12 LNs
examined or showing tumor nodules with LN-like
shape in the peri-intestinal fat were excluded from
the study. Lymph nodes were bisected and three
consecutive 5–mm-thick sections were cut from each
paraffin wax block containing LNs. The original
histologic slides of both the tumors and LNs were
reviewed by the same pathologist (LM), who had no
knowledge of each patient_s outcome. All cases were
confirmed to be free of LN metastases.
Tumor morphology and size were ascertained
from the original pathologic reports. Tumor mor-
phology was classified as exophytic or nonexo-
phytic. We categorized tumor size into two groups,
e5 cm and >5 cm, on the basis of the mean value of
the maximum diameter of the tumors. Microscopic
assessment included the recording of tumor histo-
type, tumor grade, tumor growth pattern, peritu-
moral lymphocytic infiltrate, desmoplastic response,
Crohn_s-like lymphoid reaction, involvement of ex-
tramural veins and lymphatic vessels, and extent of
tumor spread beyond muscularis propria. Tumors
were classified as mucinous or nonmucinous,
according to the amount of the mucinous component
(respectively, more or less than 50 percent of tumor
volume). Tumor grade was categorized as low grade,
including well or moderately differentiated carcino-
mas, and high grade, including poorly differentiated,
undifferentiated, and mucinous cancers.
The pattern of tumor growth, expanding or
infiltrating, was assessed according to criteria defined
by Jass et al.18 In particular, the growth pattern was
classified as expanding when advancement of the
tumor was clearly evident and the tumor had pushed
into the surrounding tissues, thus creating a well-
delineated border. It was defined as infiltrating when
the tumor dissected the muscularis propria and peri-
intestinal tissues with small glands or irregular
clusters or cords of cells without a distinct border.
Peritumoral lymphocytic infiltrate was defined as
conspicuous when there was a distinctive cuff of
lymphocytes at the invasive margin of tumor growth
or as little/absent when the lymphocytic cuff was not
present, in accordance with criteria set by Jass et al.18
Desmoplasia was evaluated at the advancing edge of
the tumor and categorized as extensive when most of
the tumor area was surrounded by fibrosis or as
nonextensive in the remaining cases, according to
the criteria defined by Halvorsen and Seim.19 Crohn_s-
like lymphoid reaction at the invasive margin of the
tumors was classified as absent or present according
to the criteria established by Harrison et al.20 Involve-
ment of extramural veins and lymphatic vessels was
assessed according to the criteria of Talbot et al.21 The
extent of tumor spread was determined as a measure-
ment from the outer border of the longitudinal muscle
layer to the most distant point of tumor spread and
divided into two groups: slight/moderate if e 5 mm,
and extensive if > 5 mm.
To allow the maximal standardization and repro-
ducibility of our results, pathologic evaluation of all
these parameters was reviewed according to the
guidelines recently proposed by the Colorectal
Working Group of the AJCC.22
Immunohistochemical Staining and Lymph
Node Micrometastases Definition
For each case, 12 new serial 5–mm-thick sections
were obtained from the original paraffin blocks of
the recovered LNs and were mounted on microscope
slides. Staining procedures were conducted by using
an automated immunostainer (Ventana NexES\;
Ventana Medical Systems, Tucson, AZ). Sections
were deparaffinized in xylene and rehydrated in a
descending ethanol series. Microwave-based heat-
induced epitope retrieval was performed. Endoge-
nous peroxidase activity was blocked by immersion
for ten minutes in 0.3 percent hydrogen peroxide in
methanol solution, followed by a single wash in
phosphate-buffered saline (PBS; pH 7.4). Sections
were incubated with the monoclonal antibody anti-
cytokeratin 20 (CK20) (clone Ks20.8\, Cell Marque
Corporation, Hot Springs, AR). The immunostaining
was developed by using 3,30-diaminobenzidine as
chromogen. Appropriate positive and negative con-
trols were added on each automated immunohisto-
chemistry run to confirm the sensitivity and
specificity of the antibody (sections of CK20-positive
CRC tissue served as positive controls; negative
controls were obtained by omitting the primary
antibody). The immunostained slides were evaluated
by the same pathologist (LM), who had no knowl-
edge of pathologic data or each patient_s outcome.
Clusters of cells detected by CK20 immunostaining
were considered as metastases only when they
showed unequivocal morphologic features of cancer
cells. According to the sixth edition of the TNM
system by the AJCC,8 immunostained tumor cells
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found in LNs were classified as MCM only when
tumor deposits measured > 0.2 mm but < 2.0 mm
(Fig. 1).
Statistical Analysis
Survival time was calculated from the date of
surgery to the date of death or last follow-up. The
relationship between pathologic variables and sur-
vival was estimated by using the Kaplan-Meier
method.23 Differences among the survival curves
were tested for statistical significance with the help
of the log-rank test. The Cox proportional hazard
regression model24 was used to identify the patho-
logic factors that could independently influence
survival. STATA\ Statistical Software release 6.0
(College Station. TX) was used for all the analyses.
P < 0.05 was considered significant.
RESULTS
Pathologic data regarding the 238 patients are
summarized in Table 1. At the time of analysis, no
patients were lost to follow-up and there had been
53 cancer-related deaths. Among these, 46 were
caused by distant metastases and 7 by locoregional
recurrence after resection of rectal tumors. When all
238 patients were considered, the eight-year survival
rate was 77.3 percent (Fig. 2). Intraobserver agree-
ment on growth pattern and lymphocytic infiltrate
evaluation were evaluated in 85 patients by measur-
ing the k coefficient. These patients were examined
for the first time by our pathologist (LM) in 20025 and
then reevaluated for the present study. The k value
reached 0.91 and 0.82 for the two parameters,
respectively, thus demonstrating almost perfect
agreement.
Among the pathologic parameters estimated, tu-
mor growth pattern, Crohn_s-like lymphoid reaction,
extent of spread beyond muscularis propria, and LN
MCM were shown to be significantly correlated to
patient survival according to univariate analysis
(Table 2). Survival was analyzed within each group
of patients with different tumor location: the prog-
nostic value of all the pathologic features did not
significantly differ between patients with colon and
those with rectal tumors (data not shown). Among
the four prognostic parameters, Cox regression
analysis selected the growth pattern and the extent
of spread beyond muscularis propria as having an
independent prognostic value (Table 3). On the basis
of this result, patients were classified into four groups
considering all the possible combinations of the two
independent prognostic factors. No significant differ-
ences in median age, male/female ratio, and tumor
location were found among the four subsets (data
not shown). The survival rates of these groups were
evaluated and compared (Table 4). Those patients
with tumors having an infiltrating growth pattern in
combination with extensive extramural spread
showed a 53.4 percent eight-year survival rate,
whereas the other three groups, when pooled to-
gether, showed a comprehensive eight-year survival
rate of 83.3 percent. Therefore, two distinct groups—
high-risk and low-risk—with a significant difference
in survival rates (P < 0.0001) were identified (Fig. 3).
DISCUSSION
Patients with Stage II colorectal cancer show the
highest variability in clinical outcome with their five-
year survival rate ranging between 60 and 75
percent.3–6 The use of adjuvant therapy in these
patients remains controversial,25–28 and increasing
attention is being focused on the identification of
new factors, which may enable a more accurate
patient prognostic stratification within this stage.
According to recommendations of the new AJCC
sixth cancer staging edition,8 recent studies have
demonstrated that patients with Stage IIB (T4N0)
tumors have a significantly worse prognosis than
patients with Stage IIA (T3N0) tumors,9 suggesting
Figure 1. Immunohistochemical staining for cytokeratin
20 (CK20). A cluster of CK20-positive cells classified as
micrometastasis (>0.2 mm and e2 mm) was detected in
the peripheral sinus of a lymph node (original magnifica-
tion 200; bar = 100 mm).
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that patients classified as Stage IIB may benefit from
adjuvant therapies. Based on these results, our study
exclusively focused on patients classified as Stage IIA
to identify new subgroups of patients at high risk of
tumor relapse by analyzing the actual prognostic
impact of a wide spectrum of pathologic parameters.
A pivotal step in classifying a tumor as Stage II is
the accuracy of LN harvesting and examination. The
AJCC recommends that a minimum of 12 LNs be
examined to accurately predict node negativity in
colorectal cancer, and recent studies have shown that
the five-year survival rate of patients classified as
Stage II progressively increases with the number of
nodes examined.29 If few lymph nodes are exam-
ined, there is an increased risk that at least one
metastatic LN is missed in the resected specimen and
thus, a patient who is truly Stage III is mistakenly
classified as Stage II.5,30 As a consequence, we
included in the present study only those patients
with at least 12 harvested and examined LNs, reach-
ing a median value of 18 LNs sampled when all 238
patients were considered. To both improve accuracy
of pathologic examination and evaluate the potential
Figure 2. Kaplan-Meier survival curve of 238 patients
with Stage IIA colorectal cancer.
Table 1.
Categorization of Pathologic Parameters in 238 Patients with Stage IIA Colorectal Cancer
Parameter No. of Patients (%)
Tumor morphology
Exophytic 107 (45)
Nonexophytic 131 (55)
Maximum diameter of tumor (cm)
e5 113 (47.5)
>5 125 (52.5)
Tumor type
Mucinous 34 (14.3)
Nonmucinous 204 (85.7)
Tumor grade
High 78 (32.8)
Low 160 (67.2)
Growth pattern
Expanding 87 (36.6)
Infiltrating 151 (63.4)
Peritumoral lymphocytic infiltrate
Little/absent 192 (80.7)
Conspicuous 46 (19.3)
Desmoplastic response
Nonextensive 189 (79.4)
Extensive 49 (20.6)
Crohn_s-like lymphoid reaction
Present 69 (29)
Absent 169 (71)
Venous invasion
Present 56 (23.5)
Absent 182 (76.5)
Lymphatic vessel invasion
Present 53 (22.3)
Absent 185 (77.7)
Extent of spread
Slight/moderate 156 (65.5)
Extensive 82 (34.5)
Lymph node micrometastases
Present 20 (8.4)
Absent 218 (91.6)
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prognostic impact of nodal occult metastases in our
patients, we investigated the presence of nodal
CK20-positive tumor cells missed during routine
hematoxylin-eosin staining. We considered as true
MCM only those tumor cell clusters that measured
> 0.2 mm but < 2.0 mm. MCM have been shown to be
the only type of nodal occult disease to have
metastatic activities, such as cell proliferation, stromal
reaction, or extravasation,17 and are designated as
pN1 (mi) by the most recent TNM-AJCC classification.8
Our survival analysis confirmed this datum, showing a
worse prognosis in patients with MCM than in those
without them. However, the presence of MCM did not
show an independent effect on survival at multivariate
Table 3.
Multivariate Analysis of Prognostic Factors Using Cox Proportional Hazard Regression Model
Prognostic Factors Comparison
Hazards Ratio
(95% CI) P Value
Growth pattern Infiltrating vs. expanding 2.24 (1.18–4.286) 0.01
Crohn_s-like lymphoid reaction Absent vs. present 1.8 (0.873–3.728) 0.1
Extent of spread beyond muscularis propria Extensive vs. slight/moderate 1.95 (1.134–3.38) 0.04
Lymph node micrometastases Present vs. absent 1.6 (0.731–3.507) 0.23
Table 2.
Univariate Analysis of Pathologic Parameters in 238 Patients with Stage IIA Colorectal Cancer
Parameter Eight-Year Survival (%) P Value
Tumor site 0.31
Proximal colon 82.3
Distal colon 78.8
Rectum 72.5
Tumor morphology 0.22
Exophytic 81.3
Nonexophytic 74.8
Maximum diameter of tumor (cm) 0.1
e5 82.3
>5 73.6
Tumor type 0.12
Mucinous 67.6
Nonmucinous 79.4
Tumor grade 0.12
High 71.7
Low 80.5
Growth pattern 0.01
Expanding 86.2
Infiltrating 72.8
Peritumoral lymphocytic infiltrate 0.19
Little/absent 84.7
Conspicuous 76
Desmoplastic response 0.29
Nonextensive 79.3
Extensive 71.4
Crohn_s-like lymphoid reaction 0.03
Present 86.7
Absent 73.9
Venous invasion 0.4
Present 81.8
Absent 76.3
Lymphatic vessel invasion 0.44
Present 73.5
Absent 78.9
Extent of spread 0.008
Slight/moderate 82.6
Extensive 68.2
Lymph node micrometastases 0.03
Present 60
Absent 79.3
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analysis. This is probably the result of the relatively
low incidence (8.4 percent) of MCM in our series of
patients, despite the high number of both LNs and
nodal cut sections examined.
In clinical practice, the more independent prog-
nostic factors we have, the more accurately we can
predict the clinical outcome of patients. We investi-
gated the prognostic significance of a large number
of pathologic parameters and identified two of them
as having an independent predictive value according
to multivariate analysis. Tumor growth pattern was
first proposed by Jass et al.18 in their prognostic
classification of rectal tumors in conjunction with
peritumoral lymphocytic infiltration, tumor spread,
and lymph node involvement. Although Jass_ new
grading system was shown to have superior prog-
nostic value to Dukes staging, it has not been
recommended for routine usage in standard report-
ing protocols because some studies have raised the
criticism of poor reproducibility and reliability of the
growth pattern and lymphocytic infiltrate.20,31,32 In
two previously published studies, we have shown
the lack of any prognostic significance of lympho-
cytic infiltrate but a strong correlation between tumor
growth pattern and survival in patients with LN-
negative and patients with LN-positive colorectal
cancer.3,33 In the present study, we reconfirmed
these data in patients classified as Stage IIA, thus
demonstrating, in accordance with the experience of
other authors,2,34–37 the reliability of the growth
pattern as an objective predictor of prognosis. In
particular, the College of American Pathologists
Consensus Statement in 19992 stated that the potential
subjective character of this promising prognostic factor
can be maximally reduced if its assessment rigorously
follows the definitions published by Jass et al.18
The strong correlation between the pattern of tumor
growth and clinical outcome may be explained by the
biologic relationship of this parameter with the nature of
the advancing tumor margin, which is considered the
most representative area of the tumor aggressiveness. In
fact, the pivotal steps in local invasion and metastasis of
a solid tumor are considered to be both dissociation and
migration of neoplastic cells out of the main tumor at the
invasive front.38 The evaluation of growth pattern most
likely reflects these tumor characteristics.
The other independent prognostic factor that
emerged from our survival analysis is the extent of
tumor spread beyond the muscularis propria, that is,
spread into the subserosa for colon and intraperito-
neal rectal cancer or into the mesorectum for
extraperitoneal rectal tumors. It is worth emphasizing
that subserosal involvement is not synonymous with
peritoneal involvement; subserosa and serosa are
two distinct tissue layers.39 As mentioned earlier,
peritoneal involvement has been shown to be a
strong, independent, prognostic factor in colon
cancer4,6 and has been designated with the major
local tumor stage categorization of T4 by the AJCC.8
The unfavorable prognosis linked to serosal invasion
is most likely the result of the high probability of
tumor transcoelomic dissemination at the time of
surgery6,9,39 and, thus, to incomplete tumor removal.
However, our finding of a significantly worse prog-
nosis for patients with extensive extramural spread
(>5 mm) compared with those with slight/moderate
spread (e5 mm) may be ascribed to a diffuse
Figure 3. Kaplan-Meier survival curves of low-risk and
high-risk patients with Stage IIA colorectal cancer.
Table 4.
Prognostic Grouping of 238 Patients with Stage IIA Colorectal Cancer According to the Combination of Tumor Growth
Pattern and Extent of Spread Beyond Muscularis Propria
Prognostic Factors No. of Patients (%) Eight-Year Survival (%)
Expanding and slight/moderate spread 56 (23.5) 87.5
Expanding and extensive spread 31 (13) 83.8
Infiltrating and slight/moderate spread 100 (42) 80.9
Infiltrating and extensive spread 51 (21.5) 53.4
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invasion of the blood/lymphatic vessels and nerve
fibers that are abundantly present within extramural
soft tissue. This implies a high risk for developing
hematogenous metastases or locoregional recurrence.
Although the prognostic importance of venous and
lymphatic invasion by tumor has been strongly
suggested in the literature,2 we did not find any
correlation between these two parameters and the
clinical outcome of our patients. Most studies report-
ing a prognostic value for venous invasion included
patients with Stage I to Stage IV colorectal cancer.2
However, at least four previously published studies
failed to show any prognostic impact of venous
invasion in patients with Stage II colorectal can-
cer.40–43 It might be hypothesized that invasion of blood
vessels, especially large extramural veins, is a late event
in the process of tumor spread and thus is prognostically
relevant only in patients with tumors at advanced stage
or with proven ability to establish metastases. As for
lymphatic invasion, its prognostic significance has been
reported to be linked to lymph node metastasis
prediction.44 The exclusion of potentially understaged
patients (i.e., those with < 12 lymph nodes examined in
the surgical specimen) and the low incidence of
micrometastases may explain the lack of any predictive
value of this parameter in our series of patients.
Interestingly, we found that growth pattern and
extent of local spread can be effectively combined to
provide a robust and simple prognostic model. We
were able to divide patients into two categories with
a low risk or high risk of tumor-related death. The
low-risk group resulted from the combination of
both patients with expanding tumors, independently
of the extent of tumor spread, and patients with
infiltrating tumors but slight/moderate spread. These
patients showed similar prognoses and a cumulative
83.3 percent eight-year survival rate. Although our
analysis was not comprehensive of all the possible
pathologic determinants of tumor aggressiveness
reported in the literature, the $16 percent incidence
of disease relapse in this low-risk group is most likely
caused by potential patient-related factors, such as a
deficiency in the immune response against the
tumor. The high-risk group comprised those patients
with infiltrating tumors and extensive tumor spread,
showing a cumulative 53.4 percent eight-year surviv-
al rate. This rate is similar to that reported in previous
studies for patients with Stage III or Dukes C, i.e.,
those with metastatic lymph nodes.5,9,45 As a conse-
quence, the administration of adjuvant therapy may
be justified and effective in this class of patients.
CONCLUSIONS
We investigated the predictive value of a wide
spectrum of pathologic parameters in a large series of
homogenously treated and characterized patients
with Stage IIA colorectal patients. Our survival
analysis identified both the growth pattern and
extent of local tumor spread as having independent
prognostic value. By combining these two easily
determined parameters, we were able to elaborate a
new and simple prognostic classification that could
help to identify a subset of patients with poor
outcome who may then benefit from adjuvant
therapies. However, future clinical trials using multi-
center patient cohorts should be prospectively per-
formed to evaluate the reproducibility of our results
and the opportunity of using this prognostic model
in routine practice.
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